Satellos Bioscience Inc. (MSLE) Stock: Price, Forecast & Analyst Target
Satellos Bioscience Inc. (MSLE) — MoonshotScore 33/100 (Weak band), calculated Oct 4, 2026. Price $8.50 (-0.12%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Satellos Bioscience Inc. · MSLE · NASDAQ
Satellos Bioscience Inc. is a Toronto-based regenerative medicine company focused on developing innovative therapeutics for muscle diseases. Utilizing its proprietary MyoReGenX™ technology platform, the company aims to address stem cell regeneration deficits.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Satellos Bioscience (MSLE)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and weak growth; the market is already moving on it. Business Quality: Thin; Financial Safety: Sound; Valuation: Full; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 0 of 8
- Altman Z -1.29 · Piotroski F 1
Holding back: soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak | |
| 33 | Weak |
The score was 33 in the stored Oct 3, 2026 snapshot and remains 33 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $8.50 | |
| Change on the day | -0.12% | |
| 52-week range | $5.30 – $13.39 | |
| Shares traded on the day | 27.7K |
Price & events
Other perspectives
Council score for Satellos Bioscience (MSLE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the MSLE film — every key number, told as a short cinematic story
~2 min · open the film
What is Satellos Bioscience (MSLE), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Satellos Bioscience Inc. (MSLE) is listed on NASDAQ. It employs 18 people and is led by Francis Gleeson. In Q2 FY2026 it reported revenue of $0 and net income of -$11M.
What do the latest results show for Satellos Bioscience (MSLE)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0. Against analyst estimates the company has EPS beat 0 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$11M | -$0.55 (diluted) |
| Q1 FY2026 | $0 | -$10M | -$0.53 (diluted) |
| Q4 FY2025 | $0 | -$7M | -$0.47 (diluted) |
| Q3 FY2025 | $0 | -$6M | -$0.42 (diluted) |
What are the financial strengths and risks for Satellos Bioscience (MSLE)?
Short answer
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z -1.29 · Piotroski F 1. Trailing ratios: ROE -51.4% · ROA -25.6% · current ratio 11.13 · earnings yield -56.7% · free-cash-flow yield -23.0%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.29 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-51.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
What should you watch next at Satellos Bioscience (MSLE)?
Short answer · as of
Current published price targets run low $18.00 · high $23.00 · consensus $19.67 · median $18.00 against a quoted price of $8.50 (as of Oct 2, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Satellos Bioscience compare with its peers?
Short answer
Satellos Bioscience's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $115.30 Oct 2, 2026 | $23.4B | 98 5-pillar Oct 4, 2026 | |
| $58.39 Oct 2, 2026 | $14.7B | 98 5-pillar Oct 4, 2026 | |
| $504.73 Oct 2, 2026 | $128B | 97 5-pillar Oct 4, 2026 | |
| $919.21 Oct 2, 2026 | $57.2B | 97 5-pillar Oct 4, 2026 | |
| $541.70 Oct 2, 2026 | $23.0B | 97 5-pillar Oct 4, 2026 | |
| $735.20 Oct 2, 2026 | $75.7B | 94 5-pillar Oct 4, 2026 | |
| $61.15 Oct 2, 2026 | $125B | 91 5-pillar Oct 4, 2026 | |
| $37.32 Oct 2, 2026 | $166B | 91 5-pillar Oct 4, 2026 | |
| $116.23 Oct 2, 2026 | $12.6B | 91 5-pillar Oct 4, 2026 | |
| $143.18 Oct 2, 2026 | $14.4B | 90 5-pillar Oct 4, 2026 | |
| $219.72 Oct 2, 2026 | $29.4B | 89 5-pillar Oct 4, 2026 | |
| $227.87 Oct 2, 2026 | $14.2B | 88 5-pillar Oct 4, 2026 | |
| Satellos Bioscience (MSLE) — this page | $8.50 | — | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $18.00 – $23.00
- Consensus target
- $19.67
- Median target
- $18.00
Consensus record · Captured .
Measured against a quoted price of $8.50 (as of Oct 2, 2026).
What has been published about Satellos Bioscience (MSLE)?
- Satellos Bioscience Announces WHO Assigned International Nonproprietary Name Forazapadin To SAT-3247; Says BASECAMP Enrollment Expected To Complete This Quarter, Clinical Data In Q4
- Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
- Satellos to Participate in Upcoming Investor Conferences
- LifeSci Capital Initiates Satellos Bioscience at Outperform
Satellos Bioscience Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the MSLE research dossier (written Mar 16, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for MSLE?
MSLE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Satellos Bioscience Inc. is a Toronto-based regenerative medicine company focused on developing innovative therapeutics for muscle diseases.
Is MSLE a good stock to buy?
Stock Expert AI does not rate MSLE buy, sell or hold. Satellos Bioscience Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MSLE stock price today?
The last price recorded on this page for Satellos Bioscience Inc. (MSLE) is $8.50, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MSLE price target?
The analyst consensus price target for Satellos Bioscience Inc. (MSLE) is $19.67 (range $18.00 to $23.00, median $18.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What is Satellos Bioscience Inc. Common Stock's drug pipeline status?
Satellos Bioscience Inc. is currently in the early stages of developing its drug pipeline, with a focus on therapeutics for muscle diseases.
What are the key factors to evaluate for MSLE?
Satellos Bioscience Inc. (MSLE) holds a MoonshotScore in the low range. Analysts target $19.67 (+131%). Headquartered in Toronto, Canada, providing access to a robust healthcare ecosystem. Not financial advice.
How frequently does MSLE data refresh on this page?
MSLE's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MSLE's recent stock price performance?
Satellos Bioscience Inc. (MSLE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative proprietary technology platform (MyoReGenX™). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MSLE overvalued or undervalued right now?
Satellos Bioscience Inc. (MSLE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $19.67 (+131%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (19 figures)
The 19 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 11 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $8.50 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T12:34:37.930Z. | |
px.change | Change on the day | -0.12% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.volume | Shares traded on the day | 27.7K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$11M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $18.00 · high $23.00 · consensus $19.67 · median $18.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $18.00 – $23.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $19.67 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $18.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 0 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-04 | |
fin.scores | Distress and quality screens | Altman Z -1.29 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
px.range52 | 52-week range | $5.30 – $13.39 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.employees | Employees | 18 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.ceo | Chief executive | Francis Gleeson | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -51.4% · ROA -25.6% · current ratio 11.13 · earnings yield -56.7% · free-cash-flow yield -23.0% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 33 of 100 · Weak · pillars 35 / 67 / 41 / 31 / 78 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 33 (stored snapshot Oct 3, 2026) → 33 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.